<?xml version='1.0' encoding='utf-8'?>
<document id="23532686"><sentence text="Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole."><entity charOffset="70-77" id="DDI-PubMed.23532686.s1.e0" text="aspirin" /><entity charOffset="79-99" id="DDI-PubMed.23532686.s1.e1" text="acetylsalicylic acid" /><entity charOffset="123-135" id="DDI-PubMed.23532686.s1.e2" text="dipyridamole" /><entity charOffset="206-216" id="DDI-PubMed.23532686.s1.e3" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e0" e2="DDI-PubMed.23532686.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e0" e2="DDI-PubMed.23532686.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e0" e2="DDI-PubMed.23532686.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e0" e2="DDI-PubMed.23532686.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e1" e2="DDI-PubMed.23532686.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e1" e2="DDI-PubMed.23532686.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e1" e2="DDI-PubMed.23532686.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e2" e2="DDI-PubMed.23532686.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23532686.s1.e2" e2="DDI-PubMed.23532686.s1.e3" /></sentence><sentence text="The fixed-dose combination of aspirin (acetylsalicylic acid) 25 mg plus extended-release dipyridamole 200 mg (ASA+ER-DP) is used for long-term secondary stroke prevention in patients who have experienced non-cardioembolic stroke or transient ischemic attack"><entity charOffset="30-37" id="DDI-PubMed.23532686.s2.e0" text="aspirin" /><entity charOffset="39-59" id="DDI-PubMed.23532686.s2.e1" text="acetylsalicylic acid" /><entity charOffset="89-101" id="DDI-PubMed.23532686.s2.e2" text="dipyridamole" /><pair ddi="false" e1="DDI-PubMed.23532686.s2.e0" e2="DDI-PubMed.23532686.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23532686.s2.e0" e2="DDI-PubMed.23532686.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s2.e0" e2="DDI-PubMed.23532686.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23532686.s2.e1" e2="DDI-PubMed.23532686.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s2.e1" e2="DDI-PubMed.23532686.s2.e2" /></sentence><sentence text=" Although the theoretical risk is low that the antiplatelet activity of ASA+ER-DP will be affected by concomitant use of a proton pump inhibitor (PPI), no formal drug-drug interaction studies have been conducted" /><sentence text="" /><sentence text="This study aimed to determine whether the PPI omeprazole influences the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of ASA+ER-DP"><entity charOffset="46-56" id="DDI-PubMed.23532686.s5.e0" text="omeprazole" /></sentence><sentence text="" /><sentence text="This was a randomized, open-label, multiple-dose, crossover, drug-drug interaction study carried out in a clinical trial unit" /><sentence text="" /><sentence text="Sixty healthy male and female volunteers aged 18-50 years were included in the study" /><sentence text="" /><sentence text="Participants were randomized to one of two treatment sequences (ABCD or CDAB), each comprising four 7-day treatments with a washout of ≥14 days between the second and third treatments" /><sentence text=" Treatment A=ASA+ER-DP 25 mg/200 mg (Aggrenox®) twice daily (BID) alone; B=ASA+ER-DP 25 mg/200 mg BID+omeprazole (Prilosec®) 80 mg once daily (QD) following ASA+ER-DP alone for 7 days; C=omeprazole 80 mg QD alone; D=omeprazole 80 mg QD+ASA+ER-DP 25 mg/200 mg BID following omeprazole alone for 7 days"><entity charOffset="98-112" id="DDI-PubMed.23532686.s12.e0" text="BID+omeprazole" /><entity charOffset="114-122" id="DDI-PubMed.23532686.s12.e1" text="Prilosec" /><entity charOffset="273-283" id="DDI-PubMed.23532686.s12.e2" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.23532686.s12.e0" e2="DDI-PubMed.23532686.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23532686.s12.e0" e2="DDI-PubMed.23532686.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s12.e0" e2="DDI-PubMed.23532686.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23532686.s12.e1" e2="DDI-PubMed.23532686.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23532686.s12.e1" e2="DDI-PubMed.23532686.s12.e2" /></sentence><sentence text="" /><sentence text="The main outcome measures were systemic PK exposure to ER-DP and ASA inhibition of arachidonic acid-induced platelet aggregation"><entity charOffset="83-99" id="DDI-PubMed.23532686.s14.e0" text="arachidonic acid" /></sentence><sentence text="" /><sentence text="Systemic exposure to ER-DP was similar with and without omeprazole, based on steady-state area under the concentration-time curve (AUC) from 0 to 12 h (AUC0-12,ss, ng·h/mL) and maximum plasma concentration (Cmax,ss, ng/mL)"><entity charOffset="56-66" id="DDI-PubMed.23532686.s16.e0" text="omeprazole" /></sentence><sentence text=" For the treatment comparison D versus A, the percent mean ratios were 96" /><sentence text="38 (90% confidence interval [CI] 90" /><sentence text="96-102" /><sentence text="13) for AUC0-12,ss and 92" /><sentence text="03 (86" /><sentence text="95-97" /><sentence text="40) for Cmax,ss" /><sentence text=" The ER-DP concentration versus time profiles were nearly superimposable" /><sentence text=" There was no effect on the PDs of the ASA component: the extent of ASA inhibition of arachidonic acid-induced platelet aggregation was almost identical with and without omeprazole, with a percent mean ratio for treatment D versus A = 99"><entity charOffset="86-102" id="DDI-PubMed.23532686.s25.e0" text="arachidonic acid" /><entity charOffset="170-180" id="DDI-PubMed.23532686.s25.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.23532686.s25.e0" e2="DDI-PubMed.23532686.s25.e0" /><pair ddi="false" e1="DDI-PubMed.23532686.s25.e0" e2="DDI-PubMed.23532686.s25.e1" /></sentence><sentence text="02 (90 % CI 98" /><sentence text="32-99" /><sentence text="72) at 4 h after last dose" /><sentence text=" All treatments were well tolerated" /><sentence text="" /><sentence text="The PK and PD behavior of ASA + ER-DP was not altered by concurrent administration of omeprazole"><entity charOffset="86-96" id="DDI-PubMed.23532686.s31.e0" text="omeprazole" /></sentence><sentence text="" /></document>